Accueil   Diary - News   All news MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic

MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic

 

MaaT Pharma to Provide Data Update for Lead Microbiome Biotherapeutic in Oral Presentation at 62nd American Society of Hematology (ASH) Annual Meeting

 

  • Treatment of 29 acute gastrointestinal Graft-versus-Host-Disease patients with full-ecosystem microbiome restoration biotherapeutic MaaT013 reported safe, demonstrating positive impact

 

Lyon, France, November 26, 2020 – MaaT Pharma announced today that updated results from its compassionate use program for lead microbiome therapeutic MaaT013 will be reported in an oral presentation at the virtual 62nd American Society of Hematology (ASH) Annual Meeting held from December 5 -8, 2020. The results include data from 29 patients with gastrointestinal, acute Graft-versus-Host-Disease (aGvHD) who were resistant to multiple lines of treatments and were treated with the full-ecosystem microbiome restoration biotherapeutic. MaaT Pharma provided the product to hospitals under an expanded access treatment program in France called Autorisation Temporaire d’Utilisation Nominative (ATUn). MaaT013 is an enema formulation of a microbiome biotherapeutic characterized by a consistent high diversity and richness of microbial species, derived from pooled donations from healthy individuals. The data will be presented by Dr. Florent Malard, MD, PhD, Associate Professor of Hematology at Saint-Antoine Hospital and Sorbonne University, who participated in the treatment program

 

Read the press release